New Study Links GLP-1 Drugs to Lower Pancreatic Cancer Risk

Pancreatic cancer remains one of the deadliest diseases, killing roughly three out of four patients within a year. This brutal illness is also on the rise, with cases increasing fastest among younger people and women.

For decades, the disease has claimed the lives of older adults, including actor Alan Rickman, who died at age 69 in 2016. However, new research offers a glimmer of hope for prevention.

A landmark study presented at the American Society for Clinical Oncology conference in Chicago revealed a significant protective effect. The research analyzed health records of approximately 90,000 US patients, specifically those with chronic pancreatitis and type 2 diabetes.

The findings showed that GLP-1 drugs, including Mounjaro and Ozempic, were linked to a 50 percent lower risk of developing pancreatic cancer over five years. Experts suggest these medications reduce inflammation and improve blood sugar control, which may block cancer progression.

Early lab tests support these claims, though human trials are still needed to fully confirm the mechanism. These results could lead to new treatment protocols for high-risk individuals, even those who are not overweight.

Dr. Rachna Shroff, a gastrointestinal cancer expert from the University of Arizona Cancer Center, called the findings remarkable. She noted that chronic pancreatitis is a major risk factor, making the observed drop in cancer incidence so significant.

This discovery is especially notable because patient leaflets previously listed pancreatitis as a rare side effect of these drugs. Recent large-scale data now shows no clear evidence of an increased risk of pancreatitis among users.

The pancreas is a vital, pear-shaped gland located behind the stomach that aids digestion. When inflamed, it causes acute pancreatitis, leading to severe pain, nausea, and fever. While obesity is a risk factor, gallstones and alcohol are also common causes.

Most cases of acute pancreatitis resolve within days or weeks. Yet, the new link between these weight-loss injections and cancer prevention could change how doctors approach high-risk patients tomorrow.

For those suffering from persistent or recurring inflammation, the condition can evolve into chronic pancreatitis, a long-term ailment that significantly elevates the risk of developing pancreatic cancer. However, new findings are challenging the traditional understanding of this risk. A recent study indicates that GLP-1 receptor agonists—such as the weight-loss injectables Mounjaro and Ozempic—are associated with approximately a 50 per cent reduction in the risk of pancreatic cancer over a five-year span.

The stakes are incredibly high in the UK, where roughly 10,500 individuals are diagnosed with pancreatic cancer annually. The prognosis remains grim, with more than half of patients succumbing to the disease within three months of diagnosis, largely because most cases are identified only after they have reached an advanced, untreatable stage.

Despite the historical concern that these drugs might slow bile and digestive enzyme flow—potentially causing components like cholesterol and gallstone fragments to clump and trigger inflammation—real-world data is telling a different story. Dr Shroff explained the initial theory: "The thinking around pancreatitis is that GLP‑1s slow the movement of bile and digestive enzymes to make users feel fuller for longer without having to eat more." While this slowing process was feared to cause blockages, emerging evidence suggests the opposite effect. "So far, there isn't any real-world data that suggests the average GLP-1 patient is at increased risk of pancreatitis or pancreatic cancer," Dr Shroff stated. "In fact, we are seeing the opposite. There's now data emerging suggesting the jabs may be protective."

This potential protective effect represents a monumental shift for a disease notoriously difficult to treat when caught late. The urgency for further research is palpable, as Dr Shroff noted, "But this is just the tip of the iceberg and we need more research to back up these claims."

Broader implications are also coming to light. Another study presented at the Asco conference proposed that these injectables could decelerate the progression of seven distinct cancer types, including lung, liver, breast, and bowel cancers, while improving survival rates. Researchers believe the mechanism may involve reducing the inflammation and excess fat surrounding tumours, effectively starving cancer cells of the fuel they need to proliferate.

Dr Brian Wolpin of the Dana-Farber Cancer Institute offered a balanced perspective on the risk-benefit profile. "There could be some trade-off if there is a higher risk of pancreatitis," he acknowledged. "But the data I have seen so far has not shown an increase in pancreatic cancer risk among users, giving us hope that these drugs could one day help in the fight against this deadly disease.